News Archives
SENOMYX, INC. NAMES ADDITIONAL BOARD MEMBERS
LA JOLLA (May 9, 2000) – Senomyx, Inc. announced today that Dr. David Schnell, Managing Partner, Prospect Venture Partners and Mr. Kevin C. Tang, Managing Director at Deutsche Banc Alex. Brown have joined the Board of Directors of the company. "We are delighted to add the impressive talents of Dr. Schnell and Mr. Tang to our already outstanding Board," stated Dr. Stryer. "This group of seasoned and experienced individuals will help ensure that Senomyx achieves its goal of becoming the world leader in the area of taste and olfaction." Also serving as members are Dr. Lubert Stryer, Chairman and Chief Scientific Officer of Senomyx; Mr. Paul A. Grayson, President and Chief Executive Officer of Senomyx; Mr. Kevin J. Kinsella, President and Chief Executive Officer of Ancile Pharmaceuticals; Dr. Lori Robson, Managing Partner, Bay City Capital; and Mr. Tim Wollaeger, General Partner, Kingsbury Capital Partners, LLP III.
Dr. James C. Blair, General Partner of Domain Associates, has relinquished his board seat, but remains an active participant in the company and now assumes the role of Board observer. "We are excited about the additions to the board and also want to thank Dr. Blair for his stellar leadership during the early stages of the company. We look forward to a continued productive relationship with him," stated Mr. Grayson.
Senomyx is dedicated to becoming the world leader in the discovery and commercialization of products and services relevant to the biology, genomics, and chemistry of chemosensation in a broad range of markets including consumer food, fragrance, cosmetic, therapeutic, household, agricultural, and industrial applications. The Company is assembling a matrix of technologies including proprietary chemoreceptors involved in the detection, quantification, signal transduction, and perception of mediators and modulators of taste, olfaction, and other sensory modalities. Senomyx has exclusive agreements with Harvard University, Johns Hopkins University, Rockefeller University, and the University of California regarding various enabling technologies in the field of chemosensation. Senomyx will utilize a range of recent advances in cellular and molecular biology, genomics, combinatorial chemistry, biomolecular screening, informatics, and other areas to create the first consumer genomics company. These technologies, developed to their full potential, will enrich the quality of life for consumers.
back to News Archives